Botulinum Neurotoxin: Mechanism of Action, Formulations, and Indications
December 13, 2022
December 31, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Catalyst Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare .
This activity is supported by an educational grant from Allergan.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Nurses — 0.5 Contact Hours
- Nurse Practitioners — 0.5 Contact Hours (.5 hour(s) of pharmacology)
All other healthcare professionals completing this course will be issued a statement of participation.
This initiative is intended for US neurologists, physiatrists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, physical therapists, and occupational therapists.
In this activity, Dr. David Simpson will discuss the clinical history of botulinum neurotoxin, its mechanism of action, and its clinical utility across various neurologic conditions. This activity will also discuss considerations for dosing, adverse events, and guideline-based use of different BoNT formulas across clinical indications. For additional activities and other information, please visit www.impact-smd.com/.
Upon completion of this activity, participants should be better able to:
- Review the mechanisms of action, indications, and clinical applications of botulinum neurotoxin therapy in patients with cervical dystonia, limb dystonias, and spasticity
- Identify the indications and unique dosing requirements of the current botulinum neurotoxins for the treatment of cervical dystonia, limb dystonias, and spasticity
David M. Simpson, MD, FAAN
Professor of Neurology
Director, Clinical Neurophysiology Laboratories
Director, Neuromuscular Division
Icahn School of Medicine at Mount Sinai
New York, New York
David M. Simpson, MD is Professor of Neurology at Icahn School of Medicine at Mount Sinai in New York, New York. He is also Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division.
Dr. Simpson received his medical degree from State University of New York at Buffalo School of Medicine. He completed an internship in internal medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in neurology at Cornell University Medical Center in New York. He had a fellowship in clinical neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.
Dr. Simpson is author of over 258 original peer-reviewed publications and 97 book chapters, has edited 3 books, and serves on numerous editorial boards. He has been the principal investigator for numerous studies, including the treatment of neuropathic pain in patients with peripheral neuropathy, neurologic complications of HIV/AIDS, and treatment of spasticity, limb dystonia, and tremor with botulinum neurotoxin. He is Chair of the American Academy of Neurology’s Subcommittee, charged with generating evidence-based guidelines for the use of botulinum neurotoxin. Dr. Simpson is a member of the American Neurological Association and the American Pain Society, Fellow of the American Academy of Neurology and the American Association of Neuromuscular and Electrodiagnostic Medicine, and President-Elect of the International Neurotoxin Association. He received the Mitchell B. Max Neuropathic Pain Award from the American Academy of Neurology in 2018, granted for outstanding achievements in the field of neuropathic pain.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
0.5 ANCC contact hours.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
This activity is approved for 0.5 contact hour(s) (which includes .5 hour(s) of pharmacology).
Disclosures of Conflicts of Interest
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
David M. Simpson, MD, FAAN, has disclosed no financial relationships.
Jessica F Marshall, PhD, Medical Writer, has no financial relationships to disclose.
Trish Brignoni, AKH Director of Operations, has disclosed no financial relationships.
Wendi Martin, AKH Continuing Education Coordinator, has disclosed no financial relationships.
AKH and Catalyst Medical Education, LLC Planners and Reviewers, have disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
If you have questions about this activity, please contact AKH Inc. at [email protected].